A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
Public ClinicalTrials.gov record NCT07321678. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
Study identification
- NCT ID
- NCT07321678
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
- Industry
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Interventions
- ASC30 tablets Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 21, 2026
- Primary completion
- Jul 31, 2026
- Completion
- Jul 31, 2026
- Last update posted
- Apr 29, 2026
2026
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ascletis Clinical Site | Riverside | California | 92506 | — |
| Ascletis Clinical Site | San Jose | California | 95128 | — |
| Ascletis Clinical Site | Denver | Colorado | 80246 | — |
| Ascletis Clinical Site | Miami | Florida | 33143 | — |
| Ascletis Clinical Site | Miami | Florida | 33172 | — |
| Ascletis Clinical Site | Decatur | Georgia | 30030 | — |
| Ascletis Clinical Site | Springfield | Missouri | 65802 | — |
| Ascletis Clinical Site | San Antonio | Texas | 78240 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07321678, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07321678 live on ClinicalTrials.gov.